Annual Report 2010/11 - Sonova

28
HearinG implantS
– a comprehensive implant product portfolio
for sustainable growth
Sonova is a global hearing care company with a strong worldwide presence
in hearing implants and hearing instruments.
With cochlear implants from the Advanced Bionics brand
and middle ear implants from the Phonak Acoustic
Implants brand, Sonova is well positioned to benefit from
the segment’s anticipated annual growth of 10–15% in
the midterm.
Through the acquisition of Advanced Bionics, Sonova has
laid the foundations for a strategic expansion of the hearing
implants segment. With targeted investments in research &
development, the geographic expansion as well as synergies
and economies of scale arising from the integration, Sonova
is in a solid position to actively drive this market segment
forward over the coming years and fully exploit sales
potential.
Following the voluntary recall of Advanced Bionics cochlear
implants in November 2010, a new course has been set
in this segment in order to return to the market. Advanced
THE HEARING IMPLANTS SEGMENT IN FIGURES
CHF sales in the
2010/11 financial year
70.8million
Bionics received CE certification from the European notified
body TÜV for changes to the manufacturing process of
the CI HiRes 90K and approval to resume distribution of
the implant in European markets in April 2011. The implant
will be reintroduced on the US market following pending
approval from the FDA.
The Ingenia middle ear implant developed by Phonak
Acoustic Implants is currently still in the development
phase. Market launch of the implant will follow after the
end of this phase.
The appointment of Hansjürg Emch to the Management
Board as Group Vice President Medical underlines the
importance of the segment, and will enable Sonova to continue
to focus and expand its strengths in this area.
4%
Share of total Group sales